ArticleBMC cancer2018

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.

Soo Young Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.